IP Library Granted Patent US 9,821,046
Granted Patent B2
US 9,821,046 · App. 14/762,106 · Granted Nov 21, 2017

Composition and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,821,046
App. No.
14/762,106
Granted
Nov 21, 2017
Kind
B2
Abstract

The present invention provides a particle comprising a fusion protein, wherein the fusion protein comprises at least one NANP repeat (SEQ ID NO: 7), some or all of the C-terminus of the CS protein from Plasmodium falciparum and a hepatitis B surface antigen, and wherein the particle comprises no, or substantially no, free hepatitis B surface antigen protein, and uses thereof.

Claims (31)

1. A virus-like particle comprising a fusion protein, wherein the fusion protein comprises at least one NANP repeat (SEQ ID NO: 7), and the C-terminus of the CS protein from Plasmodium falciparum comprising the sequence :

(SEQ ID NO: 6)

NKNNQGNGQGHNMPNDPNRNVDENANANSAVKNNNNEEPSDKIEKEYLN

KIQNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDELDYANDIEKKICK

MEKCSSVFN VVNSSIGI;

or the sequence

(SEQ ID NO: 4)

NKNNQGNGQGHNMPNDPNRNVDENANANSAVKNNNNEEPSDKHIKEYLN

KIQNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDELDYANDIEKKICK

MEKCSSV,

or a conservative substitution variant of SEQ ID No: 6 or SEQ ID NO: 4 with 95% or more sequence identity therewith; and HBsAg, wherein the virus-like particle comprises no free HBsAg.

2. The virus-like particle of claim 1 comprising at least 10 NANP repeats (SEQ ID NO: 13).

3. The virus-like particle of claim 1 , wherein the particle comprises at least about 40% or more by mass of its proteinaceous material, the proteinaceous material being derived from Plasmodium falciparum.

4. The virus-like particle of claim 1 comprising a fusion protein consisting of:

the sequence of SEQ ID NO: 1 (R21);

the sequence of SEQ ID NO: 2 (RTS); or

a sequence with at least 95%, or more sequence identity with the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

5. A fusion protein comprising at least one NANP repeat (SEQ ID NO: 7), and the C terminus of the CS protein from Plasmodium falciparum comprising the sequence :

(SEQ ID NO: 6)

NKNNQGNGQGHNMPNDPNRNVDENANANSAVKNNNNEEPSDKIEKEYLN

KIQNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDELDYANDIEKKICK

MEKCSSVFN VVNSSIGI;

or the sequence

(SEQ ID NO: 4)

NKNNQGNGQGHNMPNDPNRNVDENANANSAVKNNNNEEPSDKHIKEYLN

KIQNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDELDYANDIEKKICK

MEKCSSV;

or a conservative substitution variant of SEQ ID No: 6 or SEQ ID NO: 4 sequence with 95% or more sequence identity therewith; and HBsAg, wherein the fusion protein comprises no free HBsAg.

6. The fusion protein of claim 5 , wherein the fusion protein consists of, a sequence of SEQ ID NO: 1 (R21) or a sequence with at least 95% or more sequence identity with the sequence of SEQ ID NO: 1.

7. The fusion protein of claim 5 , wherein the fusion protein is expressed in a Saccharomyces cerevisiae or Pichia pastoris or a methylotrophic yeast cell.

8. The fusion protein of claim 7 , wherein the methylotrophic yeast cell is Hansenula polymoipha.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2018
From: COLLINS, KATHARINE ALICE; GILBERT, SARAH CATHERINE; HILL, ADRIAN VIVIAN STINTON
To: ISIS INNOVATION LIMITED
Reel/Frame 045427/0229 →
CHANGE OF NAME Recorded Aug 2, 2016
From: ISIS INNOVATION LIMITED
To: OXFORD UNIVERSITY INNOVATION LIMITED
Reel/Frame 039550/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2016
From: COLLINS, KATHARINE ALICE; GILBERT, SARAH CATHERINE; HILL, ADRIAN VIVIAN SINTON
To: ISIS INNOVATION LIMITED
Reel/Frame 038386/0239 →